Stock Performance and Market Context
On 24 March 2026, Unichem Laboratories Ltd’s stock price hit Rs.297, its lowest level in the past year. This decline represents a day change of -1.03%, with the stock underperforming the Pharmaceuticals & Biotechnology sector by -2.36%. The stock has been on a downward trajectory for two consecutive days, losing -5.13% over this period. Notably, the share price is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum.
In comparison, the broader market has also faced headwinds. The Sensex opened with a gap up of 1,516.08 points but subsequently lost 191.62 points, closing at 74,020.85, down 1.82%. The index remains 3.51% above its own 52-week low of 71,425.01 and is trading below its 50-day moving average, which itself is positioned below the 200-day moving average. The Sensex has declined by -6.21% over the past three weeks, with mega-cap stocks leading the market gains on the day.
Long-Term and Recent Financial Performance
Unichem Laboratories Ltd has experienced a challenging financial year, with its stock delivering a negative return of -57.50% over the last 12 months, significantly underperforming the Sensex’s -5.08% return in the same period. The stock’s 52-week high was Rs.727.95, highlighting the extent of the decline.
Financial metrics reveal several areas of concern. The company’s Debt to EBITDA ratio stands at a high 4.87 times, indicating a relatively low capacity to service its debt obligations. This is compounded by a Return on Equity (ROE) averaging just 1.44%, reflecting limited profitability relative to shareholders’ funds. Net sales have grown at an annual rate of 11.95% over the past five years, which, while positive, has not translated into commensurate profit growth.
Recent quarterly results further illustrate the pressures faced by the company. Profit Before Tax excluding other income (PBT LESS OI) for the quarter was Rs.6.11 crore, down sharply by -77.2% compared to the previous four-quarter average. Similarly, Profit After Tax (PAT) declined by -56.0% to Rs.16.13 crore. Interest expenses for the latest six months increased by 30.50% to Rs.15.66 crore, adding to the financial strain.
Technical Indicators and Market Sentiment
Technical analysis of Unichem Laboratories Ltd’s stock reveals predominantly bearish signals. The Moving Average Convergence Divergence (MACD) indicator is bearish on both weekly and monthly timeframes. Bollinger Bands also indicate bearish trends in the same periods. The Relative Strength Index (RSI) shows a mixed picture, with no clear signal on the weekly chart but a bullish indication monthly. Other momentum indicators such as the Know Sure Thing (KST) and Dow Theory assessments are mildly bearish, while On-Balance Volume (OBV) suggests no clear trend weekly and mild bearishness monthly.
Valuation and Peer Comparison
Despite the recent price weakness, Unichem Laboratories Ltd exhibits some valuation attributes that may be considered attractive. The company’s Return on Capital Employed (ROCE) is 4.9%, and it trades at an Enterprise Value to Capital Employed ratio of 0.9, which is considered very attractive. The stock is currently trading at a discount relative to its peers’ average historical valuations. Over the past year, while the stock price has declined by -57.50%, the company’s profits have increased by 29.9%, resulting in a Price/Earnings to Growth (PEG) ratio of 0.7.
Shareholding and Market Capitalisation
Unichem Laboratories Ltd is classified as a small-cap company within the Pharmaceuticals & Biotechnology sector. The majority shareholding is held by promoters, maintaining significant control over the company’s strategic direction.
Summary of Key Financial and Market Metrics
To summarise, the stock’s recent fall to Rs.297 marks a new 52-week low, reflecting a combination of weak profitability, elevated debt levels, and subdued market sentiment. The company’s financial results have shown declines in key profit metrics, while interest costs have risen. Technical indicators predominantly signal bearish momentum, and the stock has underperformed both its sector and the broader market indices over the past year.
Nevertheless, valuation metrics suggest the stock is trading at a discount compared to peers, supported by modest profit growth despite the price decline. The company’s long-term sales growth and ROCE provide some context to its current valuation, though these factors have not yet translated into positive share price momentum.
